The study presents a useful computational analysis of how the ratio between excitatory and inhibitory neural numbers affects coding capacity. The authors show that increasing the proportion of ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Dementia specialists have pinpointed certain eating habits as potential early indicators of frontotemporal dementia (FTD). As ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

There's no question that AI systems have accomplished some impressive feats, mastering games, writing text, and generating ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

GF9 是一种非肽配体依赖性的九肽。它由 9 个氨基酸组成，通过肽键依次连接形成线性结构 。这些氨基酸的排列顺序和侧链基团赋予了它独特的结构和功能。从二级结构预测来看，其可能存在一定的 α- 螺旋或 β- 折叠结构倾向，这取决于其所处的溶液环境和与 ...

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.